Experimental pill for advanced cancers with a KRAS mutation
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests an experimental drug (KQB368) taken as a pill. It may help people with certain cancers that have a KRAS mutation and have run out of standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like in the lung, colon, or pancreas) confirmed by biopsy.
- Your tumor has a specific mutation called KRAS G12C or KRAS G12S.
- Your cancer is advanced (has spread) or cannot be removed with surgery, and there is no treatment that can cure it.
- You are able to swallow pills and do not have a stomach or bowel problem that stops absorption of oral medicine.
- You have measurable disease (visible on scans) and your organs are working well enough.
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests an experimental pill, JAB-23E73, for people with advanced solid tumors that have a specific genetic change called KRAS. The drug may block the effects of this altered gene, potentially slowing or stopping tumor growth.
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new oral pill called HS-10529 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.